tannins 12, 16) and megastigmane glycosides 17, 18) have been found in the leaves of this plant, and some of these compounds have been reported to be biologically active, exhibiting anti-inflammatory, 2) antiviral, 5) antioxidant, 12) cytotoxic, 13) antimutagenic, 6) anti-tumor 9, 18) or hypoglycemic properties. 4) Nine triterpene acids and 2a,19a-dihydroxy-3-oxo-urs-12-en-28-oic acid isolated from E. japonica have previously been evaluated for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) and on skin tumor promotion in two stage mouse skin carcinogenesis, respectively. 9) We have investigated the anti-tumorigenic and anti-inflammatory effects 19, 20) of the triterpene acid constituents of the leaves of the same plant. In this paper, we report the isolation and identification of sixteen known triterpene carboxylic acids (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) from the methanol (MeOH) extracts of the leaves of E. japonica and their inhibitory effects on TPA-induced inflammation in mice, and on the EBV-EA activation induced by TPA. In addition, we report the inhibitory effect of euscaphic acid (12) on an in vivo two-stage mouse skin carcinogenesis.
MATERIALS AND METHODS

Instruments
1 H-NMR (400 or 600 MHz) and 13 C-NMR (150 MHz) spectra were recorded in C 5 Extraction, Isolation and Identification The dried and pulverized leaves of E. japonica (1 kg) were extracted three times with MeOH (reflux, 3 h) to yield extract (201 g). Extract (195 g) was suspended in water (4 l) and partitioned successively with n-hexane, ethyl acetate (EtOAc) and n-butanol (n-BuOH) (each 4 lϫ3 times) to yield n-hexane (9.3 g), EtOAc (48.4 g), n-BuOH (42.9 g) and H 2 O (59.0 g) fractions separately. The EtOAc-soluble fraction (23.3 g) was subjected to silica gel column chromatography.
Step gradient elution with n-hexane-EtOAc (9 : 1→0 : 1) gave fourteen fractions. Preparative reversed-phase HPLC of these fractions eventually yielded sixteen triterpene acids, 1-16 (Chart 1), which were identified as: oleanolic acid (1; ca. 2.7% in the EtOAc-soluble fraction), 21) maslinic acid (2; 1.7%), 9) methyl arjunolate (3; 0.2%), 22, 23) 2a,3a,23-trihydroxyolean-12-en-28-oic acid (4; 1.3%), 24) d-oleanolic acid (5; 0.1%), 24, 25) ursolic acid (6; 9.7%), 26) methyl ursolate (7; 0.2%), 27) corosolic acid (8; 4.4%), 9) 3-O-cis-p-coumaroyltormentic acid (9; 0.8%), 21) 3-O-trans-p-coumaroyltormentic acid (10; 4.0%), 9) 3-epicorosolic acid (11; 0.2%), 28) euscaphic acid (12; 4.9%), 29) 1b-hydroxyeuscaphic acid (13; 2.9%), 29) usrolic acid lactone (14; 0.1%), 30) betulinic acid (15; 0.1%) 31) and methyl betulinate (16; 0.1%). 32) Identification of the compounds was performed by spectral comparison with the corresponding compounds in the literature. The approximate percentage contents of individual compounds in the EtOAc-soluble fraction shown above were estimated based on the amounts of the individual fractions obtained from the EtOAc-soluble fraction and the HPLC chromatograms recorded for individual fractions.
Animals Specific pathogen-free female ICR mice were obtained from Japan SLC (Shizuoka, Japan). The animals were housed, five per polycarbonate cage, in an air-conditioned specific pathogen free room at 24Ϯ2°C. Food and water were available ad libitum.
Assay of TPA-Induced Inflammation Ear Edema in Mice TPA (1 mg, 1.7 nmol) dissolved in acetone (20 ml) was applied to the right ear of mice by means of a micropipette. A volume of 10 ml was delivered to both the inner and outer surfaces of the ear. The samples or their vehicles, MeOH-CHCl 3 -H 2 O (2 : 1 : 1, v/v/v; 20 ml), as control, were applied topically about 30 min before TPA treatment. For ear thickness determinations, a pocket thickness gauge with a range of 0-9 mm, graduated at 0.01 mm intervals and modified so that the contact surface area was increased to reduce the tension, was applied to the tip of the ear. The ear thickness was measured before treatment (a), and 6 h after TPA treatment (bϭTPA alone; bЈϭTPA plus sample). The following values were then calculated: Edema A is induced by TPA alone (bϪa).
Edema B is induced by TPA plus sample (bЈϪa). inhibitory ratio (%)ϭ[(edema AϪedema B)/edema A]ϫ100
Each value was the mean of individual determinations from 5 mice. The 50% inhibitory dose (ID 50 ) values were determined by the method of probit-graphic interpolation for four dose levels. Details of the in vivo anti-inflammatory test have been described previously.
33)
Statistical Analysis Statistical analysis was carried out by Student's t-test.
In Vitro EBV-EA Activation Experiment The inhibition of EBV-EA activation was assayed using Raji cells (EBV genome-carrying human lymphoblastoid cells; nonproducer type), cultivated in 10% fetal bovine serum RPMI-1640 medium (Sigma, St. Louis, MO, U.S.A.). The indicator cells (Raji cells; 1ϫ10 6 cells/ml) were incubated in 1 ml of the medium containing 4 mmol n-butyric acid as an inducer, 32 pmol of TPA (20 ng/ml in dimethyl sulfoxide), and a known amount (32, 16, 3 .2, 0.32 nmol) of the test compound at 37°C in a CO 2 incubator. After 48 h, cell suspensions were centrifuged at 1000 r.p.m. for 10 min, and the supernatant was removed. The activated cells were stained with high-titer EBV-EA-positive sera from nasopharyngeal carcinoma patients, and the conventional indirect immunofluorescence technique was employed for detection. In each assay, at least 500 cells were counted and the experiments were repeated three times. The average extent of EA induction was determined and compared with that on positive control experiments in which the cells were treated with n-butyric acid plus TPA where the extent of EA induction was ordinarily more than around 40%. The viability of treated Raji cells was assayed by the Trypan Blue staining method. Details of the in vitro assay on EBV-EA induction have been reported previously. 34) In Vivo Two-Stage Carcinogenesis Test on Mouse Skin Papillomas Each group was composed of 15 mice housed five per cage and given water ad libitum. The back of each mouse was shaved with surgical clippers, and the mice were topically treated with DMBA (100 mg, 390 nmol) in acetone (0.1 ml) for the initiation treatment. One week after the initiation, papilloma formation was promoted twice a week by the application of TPA (1 mg, 1.7 nmol) in acetone (0.1 ml) on the skin. Group I received the TPA treatment alone, and group II received a topically application of test sample (85 nmol) in acetone (0.1 ml) 1 h before each TPA treatment. The incidence and numbers of papillomas were observed and detected weekly for 20 weeks; only typical papillomas larger than about 1 mm in diameter were counted. Details of the in vivo two-stage carcinogenesis test have been reported previously. 35) RESULTS AND DISCUSSION The MeOH extract of E. japonica leaves and the n-hexane-, EtOAc-, n-BuOH-and H 2 O-soluble fractions obtained therefrom were examined against TPA (1.7 nmol)-induced inflammation in mice and TPA (32 pmol)-induced EBV-EA activation in Raji cells. As shown in Table 1 , the less polar nhexane-and EtOAc-soluble fractions exhibited potent inhibitory activities in both assay systems (both 87% inhibition of inflammation in mice at a dose of 1.0 mg/ear, and 66-68% inhibition of EBV-EA activation at a dose of 10 mg/ml) whereas more polar n-BuOH and H 2 O fractions showed less inhibition. The EtOAc-soluble fraction was further investigated for the active constituents in this study.
The EtOAc-soluble fraction was found to contain triterpene acid abundantly (ca. 33% in the fraction). Sixteen known compounds, viz., five of the oleanane-type (1-5), nine of the ursane-type (6) (7) (8) (9) (10) (11) (12) (13) (14) and two of the lupane-type (15, 16), were isolated and identified. Among the triterpene acids identified, 6 (ca. 9.7% in the EtOAc-soluble fraction) followed by 12 (4.9%), 8 (4.4%) and 10 (4.0%), all of which are of the ursane-type, were found more abundantly than the others.
Thirteen triterpene acids, 1-4, 6-13 and 15, were evaluated with respect to their anti-inflammatory activity against TPA-induced inflammation in mice, and the inhibitory effects were compared with those of two commercially available anti-inflammatory drugs, indomethacin and hydrocortisone, as shown in Table 2 . All of the triterpene acids tested markedly inhibited the TPA-induced inflammation [ID 50 (50% inhibitory dose)ϭ0.03-0.43 mg/ear], which being almost comparable with or more inhibitory than indomethacin (ID 50 ϭ0.3 mg/ear). Four compounds 3, 4, 10 and 13 exhibited the strongest inhibitory effects (ID 50 ϭ0.03-0.05 mg/ ear) among the others tested, which being comparable with that of hydrocortisone (ID 50 ϭ0.03 mg/ear). The inhibitory effect against TPA-induced inflammation has been demonstrated to closely parallel with that of the inhibition of tumor promotion in two-stage carcinogenesis initiated by DMBA and then by TPA, a well-known promoter, in a mouse skin model. 36) Thus, as has been pointed out recently, 9) the triterpene acids from E. japonica leaves might be expected to possess a high antitumor-promoting effect in the same animal model.
The inhibitory effect on EBV-EA activation induced by TPA was further examined as a preliminary evaluation of the potential antitumor-promoting activities of the sixteen triterpene acids. The results are shown in Table 2 , together with comparable data for b-carotene, a vitamin A precursor that has been intensively studied in cancer chemoprevention by using animal models. 37) Of the tested compounds, two compounds (12, 13) showed potent inhibitory effects with IC 50 values of 306 and 291 mol ratio/32 pmol TPA, respectively, while preserving the high viability of Raji cells, which were found to be more inhibitory than b-carotene (IC 50 ϭ397 mol ratio/32 pmol TPA). The other fourteen compounds, 1-11 and 14-16, exhibited moderate inhibitory effects (IC 50 ϭ 450-488 mol ratio/32 pmol TPA).
Compound 12, one of the most abundant triterpene acids in the EtOAc-soluble fraction as well as one of the highest inhibitory compounds against TPA-induced inflammation in mice and TPA-induced EBV-EA activation in Raji cells, was then subjected to a two-stage carcinogenesis test on mouse skin, using DMBA as an initiator and TPA as a promoter. As shown in Fig. 1 , in the positive control group, which received treatment with DMBA and TPA, there was 100% incidence of papillomas within 10 weeks of promotion ( Fig. 1A; percentage of papilloma bearers). In the group treated with DMBA, TPA and compound 12, about 27%, 53% and 73% of the mice bore papillomas after 10, 15 and 18 weeks of tumor promotion, respectively. These tumor-inhibitory effects were also seen as a reduction in the number of papillomas ( Fig. 1B ; number of papillomas per mouse) in the compound 12 treatment group. In the positive control group, 5.2 and 8.7 papillomas were formed per mouse after 10 and 18 weeks of promotion, respectively. In the group treated with DMBA, TPA and 12, only 1.4 and 4.0 papillomas were formed per mouse after the same respective periods.
Compound 12 has thus been demonstrated in this study to possess inhibitory effects on tumor promotion in mice. Simi- lar results have previously been reported for compounds 1 35, 38) and 6. 35, 38, 39) Triterpenes possessing more than one oxygen-bearing functionality, such as both a hydroxyl and carboxyl group, have been proved to possess higher inhibitory activities than 3-monohydroxy triterpenes on skin tumor promotion in an in vivo two-stage mouse skin carcinogenesis test using DMBA as an initiator and TPA as a promoter and on TPA-induced inflammation in mice. 18) Our conclusion is that the triterpene acids from MeOH extracts of E. japonica leaves might have potential importance from their cancer chemoprevention and anti-inflammatory activities. Vol. 28, No. 10 40) d) Anti-inflammatory and EBV-EA induction data taken from literature. 41) e) EBV-EA induction data taken from literature. 41) 
